Lantern Pharma Inc.

NasdaqCM:LTRN Stock Report

Market Cap: US$33.7m

Lantern Pharma Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Panna Sharma

Chief executive officer

US$684.4k

Total compensation

CEO salary percentage76.8%
CEO tenure6.4yrs
CEO ownershipn/a
Management average tenure5yrs
Board average tenure6.3yrs

Recent management updates

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Recent updates

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Nov 05
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jun 12
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Nov 06
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jul 20
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Apr 04
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

CEO Compensation Analysis

How has Panna Sharma's remuneration changed compared to Lantern Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$684kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$475k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$622kUS$432k

-US$12m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$2mUS$384k

-US$6m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$332kUS$267k

-US$2m

Dec 31 2018US$353kUS$105k

-US$2m

Compensation vs Market: Panna's total compensation ($USD684.39K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Panna's compensation has been consistent with company performance over the past year.


CEO

Panna Sharma (53 yo)

6.4yrs

Tenure

US$684,385

Compensation

Mr. Panna Sharma has been the Chief Executive Officer and President of Lantern Pharma Inc. since July 26, 2018 and has been its Director since August 29, 2018. As Chief Executive Officer, Mr. Sharma overse...


Leadership Team

NamePositionTenureCompensationOwnership
Panna Sharma
President6.4yrsUS$684.39kno data
David Margrave
CFO & Secretary6.5yrsUS$442.68kno data
Kishor Bhatia
Chief Scientific Officer & Scientific Consultant5yrsUS$283.24kno data
Nicole Leber
Investor Relations Associateno datano datano data
Peter Nara
Co-Founder & Advisorno dataUS$794.00no data
Ernest Kitt
Head of Clinical Operations1.8yrsno datano data
Marc Chamberlain
Chief Medical Officer of Starlight Therapeuticsless than a yearno datano data

5.0yrs

Average Tenure

63yo

Average Age

Experienced Management: LTRN's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Panna Sharma
President6.3yrsUS$684.39kno data
Vijay Chandru
Independent Director5.2yrsUS$46.00kno data
Maria Maccecchini
Independent Director2.5yrsUS$51.00kno data
Donald Keyser
Independent Chairman6.9yrsUS$56.00k0.39%
$ 131.0k
David Silberstein
Independent Director6.5yrsUS$46.00kno data

6.3yrs

Average Tenure

71yo

Average Age

Experienced Board: LTRN's board of directors are considered experienced (6.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:29
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lantern Pharma Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserColliers Securities
Ashok KumarThinkEquity LLC
John VandermostenZacks Small-Cap Research